What is HC Wainwright’s Estimate for IN8bio Q1 Earnings?

IN8bio, Inc. (NASDAQ:INAB) – Investment analysts at HC Wainwright issued their Q1 2027 EPS estimates for IN8bio in a research note issued on Monday, May 11th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings per share of ($0.39) for the quarter. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for IN8bio’s current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for IN8bio’s Q2 2027 earnings at ($0.41) EPS, Q3 2027 earnings at ($0.42) EPS and Q4 2027 earnings at ($0.29) EPS.

IN8bio (NASDAQ:INAB) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.33.

INAB has been the subject of several other reports. Zacks Research raised shares of IN8bio to a “hold” rating in a research note on Thursday, January 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IN8bio in a research note on Tuesday, April 21st. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $4.00.

IN8bio Trading Up 2.8%

INAB opened at $1.63 on Tuesday. IN8bio has a 1-year low of $1.17 and a 1-year high of $5.61. The company has a market cap of $16.01 million, a P/E ratio of -0.62 and a beta of 0.08. The company has a fifty day moving average price of $1.59 and a two-hundred day moving average price of $1.81.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. 683 Capital Management LLC acquired a new position in shares of IN8bio during the fourth quarter valued at about $1,696,000. Captrust Financial Advisors acquired a new position in shares of IN8bio during the fourth quarter valued at about $43,000. Alyeska Investment Group L.P. grew its holdings in shares of IN8bio by 1,060.8% during the fourth quarter. Alyeska Investment Group L.P. now owns 957,484 shares of the company’s stock valued at $2,231,000 after buying an additional 875,000 shares during the last quarter. HRT Financial LP acquired a new position in shares of IN8bio during the fourth quarter valued at about $34,000. Finally, Franklin Resources Inc. grew its holdings in shares of IN8bio by 381.6% during the fourth quarter. Franklin Resources Inc. now owns 914,531 shares of the company’s stock valued at $2,048,000 after buying an additional 724,637 shares during the last quarter. 92.05% of the stock is currently owned by institutional investors and hedge funds.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.